Skip to main content
SpringerLink
Log in

Die Nachsorge von Patienten nach MitraClip®-Implantation

Aftercare of patients after MitraClip® implantation

  • Übersichten
  • Published:
Herz Aims and scope Submit manuscript

Zusammenfassung

Viele Patienten mit mittel- bis hochgradiger Mitralklappeninsuffizienz kommen aufgrund ihrer Multimorbidität für eine operative Therapie nicht mehr in Frage. Für sie stellt das MitraClip®-Verfahren eine therapeutische Alternative dar.

Ziel des vorliegenden Artikels ist es, Empfehlungen für die Nachbehandlung einer MitraClip®-Versorgung aufzuzeigen. Hierfür wurde eine selektive Literaturübersicht anhand der aktuellen Veröffentlichungen unter besonderer Beachtung der nationalen und internationalen Leitlinien durchgeführt.

Bei Patienten nach MitraClip®-Behandlung ist wegen der zugrunde liegenden Herzinsuffizienz und nach der Herzklappenbehandlung eine Rehabilitationsmaßnahme indiziert. Neben einer Optimierung der medikamentösen Therapie erfolgen die Durchführung einer standardisierten Herzinsuffizienzschulung, die Initiierung eines Kraft- und Ausdauertrainings und eine psychosoziale Betreuung. Die Betroffenen werden außerdem über die Endokarditisprophylaxe für mindestens sechs Monate aufgeklärt. Weiterhin gilt es, die leitliniengerechte, medikamentöse Therapie mit ACE-Hemmern, Betablockern und Aldosteronantagonisten zu optimieren. Eine Besonderheit stellt die Gerinnungshemmung dar, die derzeit nur empirisch belegt ist und bei Sinusrhythmus typischerweise für vier Wochen mit dualer Thrombozytenaggregationshemmung (ASS + Clopidogrel), gefolgt von einer Monotherapie mit ASS, durchgeführt wird. Bei Vorhofflimmern wird eine lebenslange orale Antikoagulation für vier Wochen mit einem Thrombozytenaggregationshemmer kombiniert.

Bei den in der Rehabilitationsklinik und dem niedergelassenen Kardiologen durchzuführenden echokardiographischen Kontrollen muss das Augenmerk insbesondere auf einen residualen Vorhofseptumdefekt, den transmitralen Gradienten sowie eine Restinsuffizienz gelegt werden.

Abstract

Many patients with moderate to severe mitral regurgitation cannot be subjected to surgical therapy due to their multimorbidity. For these patients, MitraClip® implantation is a therapeutic alternative.

The aim of this article is to present recommendations for treatment after a MitraClip® procedure. For this purpose, a selective literature review has been carried out based on the current literature, notably on national and international guidelines.

After a MitraClip® procedure, rehabilitation is indicated because of the underlying heart failure as well as the treatment of a heart valve. Here, optimization of drug therapy, implementation of standardized heart failure training, the initiation of strength and endurance training and psychosocial support are initiated. Patients will be briefed on endocarditis prophylaxis lasting for at least six months. Furthermore, according to current guidelines, treatment with ACE inhibitors, beta-blockers and aldosterone antagonists are optimized. A special feature is anticoagulation, which is currently empirically accounted for and performed in sinus rhythm typically for four weeks of dual antiplatelet therapy (aspirin and clopidogrel) followed by a monotherapy with aspirin. In atrial fibrillation, lifelong oral anticoagulation is indicated combined with a platelet aggregation inhibitor for four weeks.

In particular, echocardiographic control in the rehabilitation clinic and by cardiologists has to be focused on a residual atrial septal defect, the transmitral gradient and a residual mitral regurgitation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Klein A, Burstow D, Tajik A, Zachariah PK et al (1990) Age-related prevalence of valvular regurgitation in normal subjects: A comprehensive color flow examination of 118 volunteers. J Am Soc Echo 3:54–63

    Article  CAS  Google Scholar 

  2. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS et al (2006) Burden of valvular heart diseases: A population-based study. Lancet 368:1005–1011

    Article  PubMed  Google Scholar 

  3. Iung B, Baron G, Butchart EG, Delahaye F et al (2003) A prospective survey of patients with valvular heart disease in Europe: The Euro heart survey on valvular heart disease. Eur Heart J 24:1231–1243

    Article  PubMed  Google Scholar 

  4. Cioffi G, Tarantini L, De Feo S, Pulignano G et al (2005) Functional Mitralklappeninsuffizienz predicts 1‑year mortality in elderly patients with systolic chronic heart failure. Eur J Heart Fail 7:1112–1117

    Article  PubMed  Google Scholar 

  5. Grigioni F, Tribouilloy C, Avierinos JF, Barbieri A et al (2008) Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. JACC Cardiovasc Imaging 1:133–141

    Article  PubMed  Google Scholar 

  6. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D et al (2005) Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 352:875–883

    Article  CAS  PubMed  Google Scholar 

  7. Enriquez-Sarano M, Basmadjian AJ, Rossi A, Bailey KR et al (1999) Progression of mitral regurgitation: A prospective Doppler echocardiographic study. J Am Coll Cardiol 34:1137–1144

    Article  CAS  PubMed  Google Scholar 

  8. Bursi F, Barbieri A, Grigioni F, Reggianini L et al (2010) Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study. Eur J Heart Fail 12:382–388. doi:10.1093/eurjhf/hfq014

    Article  PubMed  Google Scholar 

  9. Ahmed A, Aronow WS, Fleg JL (2006) Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J 151:444–450

    Article  PubMed  PubMed Central  Google Scholar 

  10. Otto C (2003) Timing of surgery in mitral regurgitation. Heart 89:100–105

    Article  PubMed  PubMed Central  Google Scholar 

  11. Montant P, Chenot F, Robert A, Vancraeynest D et al (2009) Long-term survival in asymptomatic patients with severe degenerative mitral regurgitation: A propensity score-based comparison between an early surgical strategy and a conservative treatment approach. Thorac Cardiovasc Surg 138:1339–1348. doi:10.1016/j.jtcvs.2009.03.046

    Article  Google Scholar 

  12. Seeburger J, Borger MA, Falk V, Kuntze T et al (2008) Minimal invasive mitral valve repair for mitral regurgitation: results of 1339 consecutive patients. Eur J Cardiothorac Surg 34:760–765. doi:10.1016/j.ejcts.2008.05.015

    Article  PubMed  Google Scholar 

  13. Patel JB, Borgeson DD, Barnes ME, Rihal CS et al (2004) Mitral regurgitation in patients with advanced systolic heart failure. J Card Fail 10:285–291

    Article  PubMed  Google Scholar 

  14. Mirabel M, Iung B, Baron G, Messika-Zeitoun D et al (2007) What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 28:1358–1365

    Article  PubMed  Google Scholar 

  15. Boekstegers P, Hausleiter J, Baldus S, Bardeleben RS von et al (2013) Interventionelle Behandlung der Mitralklappeninsuffizienz mit dem MitraClip®-Verfahren. Kardiologe 7:91–104. doi:10.1007/s12181-013-0492-5

    Article  Google Scholar 

  16. Rogers JH, Franzen O (2011) Percutaneous edge-to-edge MitraClip therapy in the management of mitral regurgitation. Eur Heart J 32:2350–2357. doi:10.1093/eurheartj/ehr101

    Article  PubMed  Google Scholar 

  17. Feldman T, Kar S, Rinaldi M, Fail P et al (2013) Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 54:686–694. doi:10.1016/j.jacc.2009.03.077

    Article  Google Scholar 

  18. Vakil K, Roukoz H, Sarraf M, Krishnan B et al (2014) Safety and efficacy of the MitraClip® system for severe mitral regurgitation: a systematic review. Catheter Cardiovasc Interv 84:129–136. doi:10.1002/ccd.25347

    Article  PubMed  Google Scholar 

  19. Eggebrecht H, Schelle S, Puls M, Plicht B et al (2015) Risk and outcomes of complications during and after Mitraclip implantation: experience in 828 patients from the german TRAnscatheter mitral valve interventions (TRAMI) registry. Catheter Cardiovasc Interv 86:728–735. doi:10.1002/ccd.25838

    Article  PubMed  Google Scholar 

  20. Maisano F, Franzen O, Baldus S, Schäfer U et al (2013) Percutaneous mitral valve interventions in the real world: Early and 1‑year results from the ACCESS-EU, A prospective, multicenter, nonrandomized post-approval study of the Mitraclip therapy in Europe. J Am Coll Cardiol 62:1052–1061. doi:10.1016/j.jacc.2013.02.094

    Article  PubMed  Google Scholar 

  21. Toggweiler S, Zuber M, Sürder D, Biaggi P et al (2014) Two-year outcomes after percutaneous mitral valve repair with the MitraClip system: durability of the procedure and predictors of outcome. Open Heart 1:e000056 (eCollection 2014). doi:10.1136/openhrt-2014-000056.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Baldus S, Schillinger W, Franzen O, Bekeredjian R et al (2012) German Transcatheter Mitral Valve Interventions (TRAMI) investigators. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 14:1050–1055

    Article  PubMed  Google Scholar 

  23. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J 33:1787–1847

    Article  PubMed  Google Scholar 

  24. Hasenfuß G, Anker S, Bauersachs J, Böhm M et al (2013) Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Behandlung der akuten und chronischen Herzinsuffizienz. Kardiologe 7:105–114

    Article  Google Scholar 

  25. Cosín J, Díez J, TORIC investigators (2002) Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4:507–513

    Article  PubMed  Google Scholar 

  26. Mancia G, Fagard R, Narkiewicz K, Redon J et al (2013) ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC). Eur Heart J 34:2159–2219. doi:10.1093/eurheartj/eht151

    Article  PubMed  Google Scholar 

  27. Maggioni AP, Greene SJ, Fonarow GC, Böhm M et al (2013) Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J 34:3117–3127. doi:10.1093/eurheartj/eht342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Vanhees L, Geladas N, Hansen D, Kouidi E et al (2012) Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol 19:1005–1033

    Article  CAS  PubMed  Google Scholar 

  29. Belardinelli R, Georgiou D, Cianci G, Purcaro A (2012) 10-year exercise training in chronic heart failure: A randomized controlled trial. J Am Coll Cardiol 60:1521–1528

    Article  PubMed  Google Scholar 

  30. Morken IM, Norekval TM, Isaksen K, Munk PS et al (2013) ncreased confidence to engage in physical exertion: older ICD recipients’ experiences of participating in an exercise training programme. Eur J Cardiovasc Nurs 12:261–268. doi:10.1177/1474515111435885.

    Article  PubMed  Google Scholar 

  31. Ismail H, McFarlane JR, Dieberg G, Smart NA (2014) Exercise training program characteristics and magnitude of change in functional capacity of heart failure patients. Int J Cardiol 171:62–65. doi:10.1016/j.ijcard.2013.11.045.

    Article  PubMed  Google Scholar 

  32. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ et al (2009) Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301:1439–1450. doi:10.1001/jama.2009.454

    Article  PubMed  PubMed Central  Google Scholar 

  33. Mezzani A, Corra U, Bosimini E, Giordano A, Giannuzzi P (2003) Contribution of peak respiratory exchange ratio to peak VO2 prognostic reliability in patients with chronic heart failure and severely reduced exercise capacity. Am Heart J 145:1102–1107

    Article  PubMed  Google Scholar 

  34. Guazzi M, Adams V, Conraads V, Halle M et al (2012) EACPR/AHA joint scientific statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J 33:2917–2927

    Article  PubMed  Google Scholar 

  35. Rognmo O, Moholdt T, Bakken H, Hole T et al (2012) Cardiovascular risk of high- versus moderate-intensity aerobic exercise in coronary heart disease patients. Circulation 126:1436–1440. doi:10.1161/CIRCULATIONAHA.112.123117

    Article  PubMed  Google Scholar 

  36. Fischer KID, Karbach J, Link A et al (2012) Cognitive function in patients with decompensated heart failure: The cognitive impairment in heart failure (cogimpair-HF) study. Eur J Heart Fail 14:404–413. doi:10.1093/eurjhf/hfs015

    Article  PubMed  Google Scholar 

  37. Hesslinger B, Härter M, Barth J, Klecha D et al (2002) Comorbidity of depressive disorders and cardiovascular diseases. Implications for diagnosis, pharmaco- and psychotherapy. Nervenarzt 73:205–217 (quiz 218)

    Article  CAS  PubMed  Google Scholar 

  38. Bittner V, Weiner DH, Yusuf S, Rogers WJ et al (1993) Prediction of mortality and morbidity with a 6‑minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA 270:1702–1707

    Article  CAS  PubMed  Google Scholar 

  39. Steinke EE, Jaarsma T, Barnason SA, Byrne M et al (2013) Sexual counselling for individuals with cardiovascular disease and their partners: A consensus document from the American Heart Association and the ESC Council on Cardiovascular Nursing and Allied Professions (CCNAP). Eur Heart J 34:3217–3235. doi:10.1093/eurheartj/eht270.

    Article  PubMed  Google Scholar 

  40. Bjarnason-Wehrens B, Held K, Karoff M (2006) Heart groups in Germany-current situation and prospects. Herz 31:559–565

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paracelsus-Harz-Klinik Bad Suderode, Paracelsusstr. 1, 06485, Quedlinburg, Deutschland

    A. Schlitt

  2. Medizinische Fakultät, Martin Luther-Universität Halle-Wittenberg, Halle-Wittenberg, Deutschland

    A. Schlitt & H. Schmidt

  3. Klinik für Allgemeine und Interventionelle Kardiologie, Universitäres Herzzentrum Hamburg, Hamburg, Deutschland

    E. Lubos

  4. Reha-Klinik am Sendesaal, Bremen, Deutschland

    M. Guha

  5. Kardiologisch-Angiologische Praxis, Herzzentrum Bremen, Bremen, Deutschland

    C. Hegeler-Molkewehrum

  6. Klinik für Kardiologie und Diabetologie, Klinikum Magdeburg gGmbH, Magdeburg, Deutschland

    M. Sudau & H. Schmidt

Authors
  1. A. Schlitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Lubos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Guha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Hegeler-Molkewehrum
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Sudau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Schlitt.

Ethics declarations

Interessenkonflikt

A. Schlitt wurde honoriert für Beratertätigkeit (Advisory Board) von den Firmen Boehringer Ingelheim und Astra Zeneca. Er bekam Vortragshonorare und erhielt Kongressgebühren- und Reisekostenerstattung von den Firmen Sanofi-Aventis, BMS, Pfizer, Novartis, Servier, Boehringer Ingelheim, MSD, Bayer AG, u.a. Studienunterstützung (Drittmittel) wurde ihm zuteil von den Firmen GSK, Sanofi-Aventis, Mitsubishi, Endotis, Bayer AG, Boehringer Ingelheim, Novartis, Actelion, BMS, u. a. E. Lubos erhielt Vortragshonorare, Studienunterstützung und Reisekosten von Abbott. C. Hegeler-Molkewehrum erhilet Vortragshonorare von Berlin Chemie sowie Kongressgebühr-, Hotel- und Reisekostenerstattung von Medtronic, Boston, Occlutech und Bayer AG. M. Guha, M. Sudau und H. Schmidt geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schlitt, A., Lubos, E., Guha, M. et al. Die Nachsorge von Patienten nach MitraClip®-Implantation. Herz 42, 176–185 (2017). https://doi.org/10.1007/s00059-016-4448-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-016-4448-y

Schlüsselwörter

Keywords

Search

Navigation